Volume 7, Issue 4 (10-2019)                   JoMMID 2019, 7(4): 89-92 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sadat Larijani M, Sadat S M, Bolhassani A, Ramezani A. A Shot at Dendritic Cell-Based Vaccine Strategy against HIV-1. JoMMID. 2019; 7 (4) :89-92
URL: http://jommid.pasteur.ac.ir/article-1-212-en.html
Department of Clinical Research, Pasteur Institute of Iran, Tehran, Iran.
Abstract:   (2191 Views)
Introduction: Despite considerable efforts to control AIDS pandemic, it is still one of the significant infectious concerns worldwide. The advance in medical research has led to the development of highly active antiretroviral therapy with a considerable effect to suppress the disease. However, an effective vaccine capable of eradication the HIV pandemic is not available yet. Failure to develop a prophylactic vaccine diverted the efforts to clinical trials of therapeutic vaccines. Methods: Here, we review different approaches to dendritic cell-based HIV therapeutic vaccines. We have summarized the dendritic cell-based trials as HIV therapeutic vaccination, registered in the United States clinical trial database. Results and Conclusion: The strategies applied in the clinical trials were mostly of low success rates; however, by using dendritic cell therapy, they could trigger the host immune response against HIV-1 infections.
Full-Text [PDF 365 kb]   (168 Downloads)    
Type of Study: Review article | Subject: Infectious diseases and public health
Received: 2019/08/14 | Accepted: 2019/12/16 | Published: 2020/03/12

1. 1. Global HIV & AIDS statistics 2019 fact sheet [Updated 2018 Dec Cited 2019 June 18]. Available from: https://www.unaids.org/en/resources/fact-sheet
2. World Health Organization. Progress report on HIV, viral hepatitis and sexually transmitted infections 2019 [Updated 2019 Jul; Cited 2019 Jul 22]. Available from: https://www.who.int/hiv/strategy2016-2021/progress-report-2019/en/
3. Chibawara T, Mbuagbaw L, Kitenge M, Nyasulu P. Effects of antiretroviral therapy in HIV-positive adults on new HIV infections among young women: a systematic review protocol. System Rev. 2019; 8 (1): 68. [DOI:10.1186/s13643-019-0982-z]
4. Barré-Sinoussi F, Ross AL, Delfraissy JF. Past, present and future: 30 years of HIV research. Nat Rev Microbiol. 2013; 11: 877. [DOI:10.1038/nrmicro3132]
5. Larijani MS, Sadat SM, Bolhassani A, Pouriayevali MH, Bahramali G, Ramezani A. In Silico Design and Immunologic Evaluation of HIV-1 p24-Nef Fusion Protein to Approach a Therapeutic Vaccine Candidate. Curr HIV Res. 2018; 16 (5): 322-37. [DOI:10.2174/1570162X17666190102151717]
6. Larijani MS, Ramezani A, Sadat SM. Updated studies on development of HIV therapeutic vaccine. Curr HIV Res. 2019. [DOI:10.2174/1570162X17666190618160608]
7. Sosa D DR, Kaushik A, Nair M. Current status of Human Immunodeficiency Virus vaccine. Vaccin Res. 2016; 1 (1).
8. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009; 361 (23): 2209-20. [DOI:10.1056/NEJMoa0908492]
9. Odhiambo J. HIV vaccine clinical trials: An overview. Medical Writing. 2018; 27 (1): 23-9.
10. Deeks SG, Overbaugh J, Phillips A, Buchbinder S. HIV infection. Nat Rev Dis Primers. 2015; 1: 15035. [DOI:10.1038/nrdp.2015.35]
11. Demers KR, Reuter MA, Betts MR. CD8(+) T-cell effector function and transcriptional regulation during HIV pathogenesis. Immunol Rev. 2013; 254 (1): 190-206. [DOI:10.1111/imr.12069]
12. Ayyavoo DGaV. Innate Immune Evasion Strategies by Human Immunodeficiency Virus Type 1. Hindawi Publishing Corporation. 2013: 1-10. [DOI:10.1155/2013/954806]
13. Corey L GP, Tomaras GD, Haynes BF, Pantaleo G, Fauci AS. Immune correlates of vaccine protection against HIV-1 acquisition. Sci Transl Med. 2015; 7 (310): 310. [DOI:10.1126/scitranslmed.aac7732]
14. Rappuoli R AA. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature. 2011; 473 (7348): 463-9. [DOI:10.1038/nature10124]
15. Al-Jabri AA. Mechanisms of Host Resistance Against HIV Infection and Progression to AIDS. ISQUM. 2007; 7 (2): 82-96.
16. Haberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, Ronald A, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013; 10 (9): e1001511. [DOI:10.1371/journal.pmed.1001511]
17. Sela M, Hilleman MR. Therapeutic vaccines: realities of today and hopes for tomorrow. PNAS USA. 2004; 101 Suppl 2 (Suppl 2): 14559-. [DOI:10.1073/pnas.0405924101]
18. Gulley JL. Therapeutic vaccines: the ultimate personalized therapy? Hum Vaccin Immunother. 2013; 9 (1): 219-21. [DOI:10.4161/hv.22106]
19. Mona Sadat L, Seyed Mehdi S, Azam B, Mohammad Hassan P, Golnaz B, Amitis R. In Silico Design and Immunologic Evaluation of HIV-1 p24-Nef Fusion Protein to Approach a Therapeutic Vaccine Candidate. Curr HIV Res. 2018; 16 (5): 322-37. [DOI:10.2174/1570162X17666190102151717]
20. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998; 4 (3): 328-32. [DOI:10.1038/nm0398-328]
21. Saxena M, Bhardwaj N. Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment. Trends Cancer. 2018; 4 (2): 119-37. [DOI:10.1016/j.trecan.2017.12.007]
22. Sabado RL, Bhardwaj N. Dendritic-cell vaccines on the move. Nature. 2015; 519: 300. [DOI:10.1038/nature14211]
23. Miller E, Bhardwaj N. Dendritic cell dysregulation during HIV-1 infection. Immunol Rev. 2013; 254 (1): 170-89. [DOI:10.1111/imr.12082]
24. da Silva LT, Santillo BT, de Almeida A, Duarte AJdS, Oshiro TM. Using Dendritic Cell-Based Immunotherapy to Treat HIV: How Can This Strategy be Improved? Front Immunol. 2018; 9 (2993). [DOI:10.3389/fimmu.2018.02993]
25. Macatangay BJC, Riddler SA, Wheeler ND, Spindler J, Lawani M, Hong F, et al. Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells. J Infect Dis. 2016; 213 (9): 1400-9. [DOI:10.1093/infdis/jiv582]
26. Rinaldo CR. Dendritic cell-based human immunodeficiency virus vaccine. J Intern Med. 2009; 265 (1): 138-58. [DOI:10.1111/j.1365-2796.2008.02047.x]
27. Coelho AVC, de Moura RR, Kamada AJ, da Silva RC, Guimarães RL, Brandão LAC, et al. Dendritic Cell-Based Immunotherapies to Fight HIV: How Far from a Success Story? A Systematic Review and Meta-Analysis. Int J Mol Sci. 2016; 17 (12): 1985. [DOI:10.3390/ijms17121985]
28. García F, Plana M, Climent N, León A, Gatell JM, Gallart T. Dendritic cell based vaccines for HIV infection: the way ahead. Hum Vaccin Immunother. 2013; 9 (11): 2445-52. [DOI:10.4161/hv.25876]
29. U.S. National Library of Medicine. ClinicalTrials.gov. [Updated 2019 July Cited 2019 June 20]. Available from: https://clinicaltrials.gov/
30. García F, Climent N, Guardo AC, Gil C, León A, Autran B, et al. A Dendritic Cell-Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication. Sci Transl Med. 2013; 5 (166): 166ra2. [DOI:10.1126/scitranslmed.3004682]
31. Garcia F, Climent N, Guardo AC, Gil C, Leon A, Autran B, et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med. 2013; 5 (166): 166ra2. [DOI:10.1126/scitranslmed.3004682]
32. Jacobson JM, Routy JP, Welles S, DeBenedette M, Tcherepanova I, Angel JB, et al. Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J Acquir Immune Defic Syndr. 2016; 72 (1): 31-8. [DOI:10.1097/QAI.0000000000000926]
33. Cobb A, Roberts LK, Palucka AK, Mead H, Montes M, Ranganathan R, et al. Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine. J Immunol Methods. 2011; 365 (1-2): 27-37. [DOI:10.1016/j.jim.2010.11.002]
34. Macatangay BJ, Riddler SA, Wheeler ND, Spindler J, Lawani M, Hong F, et al. Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells. J Infect Dis. 2016; 213 (9): 1400-9. [DOI:10.1093/infdis/jiv582]
35. Whiteside TL, Piazza P, Reiter A, Stanson J, Connolly NC, Rinaldo CR, Jr., et al. Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection. Clin Vaccine Immunol. 2009; 16 (2): 233-40. [DOI:10.1128/CVI.00066-08]
36. Gandhi RT, Kwon DS, Macklin EA, Shopis JR, McLean AP, McBrine N, et al. Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial. J Acquir Immune Defic Syndr. 2016; 71 (3): 246-53. [DOI:10.1097/QAI.0000000000000852]
37. Patham B, Simmons GL, Subramanya S. Advances in Dendritic Cell-Based Vaccines for HIV. Curr Med Chem. 2011; 18 (26): 3987-94. [DOI:10.2174/092986711796957194]
38. Li J, Valentin A, Beach RK, Alicea C, Felber BK, Pavlakis GN. DNA is an efficient booster of dendritic cell-based vaccine. Hum Vaccin Immunother. 2015; 11 (8): 1927-35. [DOI:10.1080/21645515.2015.1020265]
39. Kulikova EV, Kurilin VV, Shevchenko JA, Obleukhova IA, Khrapov EA, Boyarskikh UA, et al. Dendritic Cells Transfected with a DNA Construct Encoding Tumour-associated Antigen Epitopes Induce a Cytotoxic Immune Response Against Autologous Tumour Cells in a Culture of Mononuclear Cells from Colorectal Cancer Patients. Scand J Immunol. 2015; 82 (2): 110-7. [DOI:10.1111/sji.12311]
40. Wu L, KewalRamani VN. Dendritic-cell interactions with HIV: infection and viral dissemination. Nat Rev Immunol. 2006; 6 (11): 859-68. [DOI:10.1038/nri1960]

Add your comments about this article : Your username or Email:

Send email to the article author

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.